Recent

% | $
Quotes you view appear here for quick access.

Vical Incorporated Message Board

  • left2rightdoor left2rightdoor Dec 27, 2012 10:49 PM Flag

    Got more shares today

    Below $3 is a good entry or addition point
    Military;s Dengue Vaccine 0 story June 2012 US Medicine
    This vaccine candidate, the culmination of 19 years of work, is the first tetravalent dengue DNA vaccine to undergo human testing. Partnering with Vical, a San Diego-based biopharmaceutical research enterprise. NMRC researchers developed the tetravalent DNA vaccine formulated with Vical’s Vaxfectin adjuvant. The Phase 1 human clinical trial that began this year is evaluating the vaccine formulated with and without Vaxfectin.

    “We partnered with Vical to use their adjuvant to enhance the immune response,” Capt. Kevin Porter, director of infectious diseases research at the Naval Medical Research Center, told U.S. Medicine.

 
VICL
4.20+0.01(+0.24%)Jul 27 4:00 PMEDT